Cargando…

Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study

OBJECTIVES: To assess differences in HIV testing at 6-months intervals over 24 months among intramuscular depot medroxyprogesterone acetate (DMPA-IM) injectable, levonorgestrel implant, or copper intrauterine devices (IUD) users in KwaZulu-Natal, South Africa, and Lusaka, Zambia. Testing at recommen...

Descripción completa

Detalles Bibliográficos
Autores principales: Beksinska, Mags, Cartwright, Alice F., Smit, Jennifer, Kasaro, Margaret, Tang, Jennifer H., Fawzy, Maria, Maphumulo, Virginia, Chinyama, Manze, Chabu, Esther, Callahan, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883203/
https://www.ncbi.nlm.nih.gov/pubmed/36718374
http://dx.doi.org/10.1016/j.conx.2023.100089
_version_ 1784879457770668032
author Beksinska, Mags
Cartwright, Alice F.
Smit, Jennifer
Kasaro, Margaret
Tang, Jennifer H.
Fawzy, Maria
Maphumulo, Virginia
Chinyama, Manze
Chabu, Esther
Callahan, Rebecca
author_facet Beksinska, Mags
Cartwright, Alice F.
Smit, Jennifer
Kasaro, Margaret
Tang, Jennifer H.
Fawzy, Maria
Maphumulo, Virginia
Chinyama, Manze
Chabu, Esther
Callahan, Rebecca
author_sort Beksinska, Mags
collection PubMed
description OBJECTIVES: To assess differences in HIV testing at 6-months intervals over 24 months among intramuscular depot medroxyprogesterone acetate (DMPA-IM) injectable, levonorgestrel implant, or copper intrauterine devices (IUD) users in KwaZulu-Natal, South Africa, and Lusaka, Zambia. Testing at recommended intervals has not been previously assessed in long-acting reversible contraceptive (LARC) users (implant and IUD users) compared to those using effective but shorter-acting methods (such as DMPA-IM) in sub-Saharan Africa. STUDY DESIGN: As part of the longitudinal contraceptive use beyond ECHO (CUBE) study, we measured HIV testing over 24 months. Participants were considered continuous users of DMPA-IM, levonorgestrel implant, or copper IUD if they used the same method across all months of their study participation, or not continuous users of their baseline CUBE method if they switched or discontinued their method. We used multivariable logistic regression models with generalized estimating equations and robust standard errors, stratified by country, to assess differences in HIV testing. RESULTS: Among the 498 participants, HIV testing rates were higher in Zambia for all methods compared to South Africa. In bivariate analyses, continuous implant or IUD users (the LARC users) were significantly less likely to report having received HIV testing at the 6-months and 24-months surveys, compared to continuous DMPA-IM users. In adjusted longitudinal models, continuous IUD users (adjusted odds ratio: 0.42, 95% CI: 0.24, 0.74), continuous implant users (adjusted odds ratio: 0.23, 95% CI: 0.12, 0.42) in South Africa had significantly lower odds of HIV testing compared to continuous DMPA-IM users. There were no significant differences in Zambia in the adjusted models. CONCLUSION: LARC use may reduce opportunities for HIV testing and users should be counseled on regular HIV testing and the option of HIV self-testing. IMPLICATIONS: Due to infrequent clinical contacts which may lead to lower rates of HIV testing at recommended intervals, LARC users should be provided opportunities to test for HIV at home or when seeking other health services.
format Online
Article
Text
id pubmed-9883203
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98832032023-01-29 Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study Beksinska, Mags Cartwright, Alice F. Smit, Jennifer Kasaro, Margaret Tang, Jennifer H. Fawzy, Maria Maphumulo, Virginia Chinyama, Manze Chabu, Esther Callahan, Rebecca Contracept X Original Research Article OBJECTIVES: To assess differences in HIV testing at 6-months intervals over 24 months among intramuscular depot medroxyprogesterone acetate (DMPA-IM) injectable, levonorgestrel implant, or copper intrauterine devices (IUD) users in KwaZulu-Natal, South Africa, and Lusaka, Zambia. Testing at recommended intervals has not been previously assessed in long-acting reversible contraceptive (LARC) users (implant and IUD users) compared to those using effective but shorter-acting methods (such as DMPA-IM) in sub-Saharan Africa. STUDY DESIGN: As part of the longitudinal contraceptive use beyond ECHO (CUBE) study, we measured HIV testing over 24 months. Participants were considered continuous users of DMPA-IM, levonorgestrel implant, or copper IUD if they used the same method across all months of their study participation, or not continuous users of their baseline CUBE method if they switched or discontinued their method. We used multivariable logistic regression models with generalized estimating equations and robust standard errors, stratified by country, to assess differences in HIV testing. RESULTS: Among the 498 participants, HIV testing rates were higher in Zambia for all methods compared to South Africa. In bivariate analyses, continuous implant or IUD users (the LARC users) were significantly less likely to report having received HIV testing at the 6-months and 24-months surveys, compared to continuous DMPA-IM users. In adjusted longitudinal models, continuous IUD users (adjusted odds ratio: 0.42, 95% CI: 0.24, 0.74), continuous implant users (adjusted odds ratio: 0.23, 95% CI: 0.12, 0.42) in South Africa had significantly lower odds of HIV testing compared to continuous DMPA-IM users. There were no significant differences in Zambia in the adjusted models. CONCLUSION: LARC use may reduce opportunities for HIV testing and users should be counseled on regular HIV testing and the option of HIV self-testing. IMPLICATIONS: Due to infrequent clinical contacts which may lead to lower rates of HIV testing at recommended intervals, LARC users should be provided opportunities to test for HIV at home or when seeking other health services. Elsevier 2023-01-16 /pmc/articles/PMC9883203/ /pubmed/36718374 http://dx.doi.org/10.1016/j.conx.2023.100089 Text en © 2023 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Beksinska, Mags
Cartwright, Alice F.
Smit, Jennifer
Kasaro, Margaret
Tang, Jennifer H.
Fawzy, Maria
Maphumulo, Virginia
Chinyama, Manze
Chabu, Esther
Callahan, Rebecca
Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title_full Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title_fullStr Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title_full_unstemmed Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title_short Is long‐acting reversible contraceptive method use associated with HIV testing frequency in KwaZulu‐Natal, South Africa and Lusaka, Zambia? Findings from the CUBE study
title_sort is long‐acting reversible contraceptive method use associated with hiv testing frequency in kwazulu‐natal, south africa and lusaka, zambia? findings from the cube study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883203/
https://www.ncbi.nlm.nih.gov/pubmed/36718374
http://dx.doi.org/10.1016/j.conx.2023.100089
work_keys_str_mv AT beksinskamags islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT cartwrightalicef islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT smitjennifer islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT kasaromargaret islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT tangjenniferh islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT fawzymaria islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT maphumulovirginia islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT chinyamamanze islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT chabuesther islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy
AT callahanrebecca islongactingreversiblecontraceptivemethoduseassociatedwithhivtestingfrequencyinkwazulunatalsouthafricaandlusakazambiafindingsfromthecubestudy